Le Lézard
Classified in: Health
Subjects: NPT, SVY, POL, SCZ, AVO

New Research: Eliminating Drugmaker Rebates Leads to Significantly Higher Medicare Part D Premiums for Seniors


WASHINGTON, July 16, 2018 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) is releasing new research showing that premiums would rise by over 50 percent if Medicare Part D plans are prohibited from negotiating rebates on brand drugs.

(PRNewsfoto/Pharmaceutical Care Management)

Manufacturers have chosen to negotiate price concessions with PBMs using rebates, which are paid months after a drug has been dispensed and are used by payers to reduce premiums and out-of-pocket costs for patients. At this time, rebates are the only usable price concession available.

Key findings from the analysis ? "Premium Impact of Removing Manufacturer Rebates from the Medicare Part D Program," include:

"Public programs like Medicaid and Medicare use rebates on brand drugs to offset high prices. Simply eliminating plans' ability to negotiate such price concessions would enrich drugmakers at the expense of patients, who'd face higher premiums and out-of-pocket costs," said PCMA President and CEO Mark Merritt. "Worse, such a policy would do nothing to reduce drug prices. A recent report by HHS' Office of Inspector General debunked the myth that drugmakers raise prices because of the discounts and rebates they negotiate with health plans and PBMs."

PCMA commissioned Oliver Wyman Actuarial Consulting to conduct the research.

PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.

SOURCE Pharmaceutical Care Management Association


These press releases may also interest you

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...

at 10:00
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.A...

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...

at 09:38
The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones....



News published on and distributed by: